Life Sciences Cluster Geography

Life sciences CRE demand is highly cluster-concentrated — unlike multifamily or industrial, which track population and logistics infrastructure, life sciences lab and cGMP manufacturing demand follows research universities, NIH funding streams, and existing biotech tenant density. The result is a small number of dominant clusters that account for the vast majority of lab space absorption, flanked by a tier of emerging markets that are attempting to attract overflow and nascent startups.

JLL's June 2026 U.S. Lab Property Report reinforces the two-speed cluster rule. JLL reports nearly 8M SF of combined Q1 demand across Boston, the Bay Area, San Diego, and Raleigh-Durham, up 44% year over year, while secondary markets lost nearly 3M SF of demand over three years and added 4.4M SF of availability. The signal is early recovery in deep clusters, not a national lab-market normalization: JLL still reports 32% collective vacancy across Boston, San Diego, and the Bay Area, concessions, shorter leases, and a near-6:1 national supply-to-demand ratio. See Source: JLL U.S. Life Sciences Real Estate Turning Point 2026.

For underwriting framework, see Life Sciences and Lab Underwriting. This page covers the geographic distribution of that demand.

Tier 1 Clusters: Established and Deep

These markets have large, institutionally capitalized lab inventories, strong university and hospital anchors, and established biotech tenant ecosystems that self-perpetuate through talent concentration and proximity to capital.

Boston / Cambridge

The deepest life sciences market in the U.S. by lab inventory concentration. Kendall Square in Cambridge is the global epicenter of biotech — MIT, Harvard, MGH, Broad Institute, and a high density of large-cap pharma R&D campuses (Novartis, Pfizer, Sanofi, AstraZeneca) sit within walking distance.

Key characteristics:

• Highest lab rents in the U.S.; Class A lab in Kendall Square has historically commanded $120–$180/SF NNN at peak
• Q4 2025: Metro-wide life sciences vacancy hit an all-time high of 28% (CBRE), with total available lab space reaching a record 17M SF. Cambridge vacancy 12.7% (12th consecutive quarterly increase). Kendall Square vacancy jumped to 9.3% (+240 bps QoQ — largest quarterly increase since Q1 2024). Cambridge rents declined to ~$93/SF from prior peaks.
• Q1 2026 (CBRE Boston Metro): Greater Boston lab availability held at 32.7%, vacancy was 27.9%, Q1 net absorption was -117,186 SF, and cumulative negative absorption since Q1 2025 exceeded 1.1M SF. This looks like marginal stabilization from Q4 2025, not a broad recovery.
• Post-2023 correction has widened availability and put landlord leverage under structural pressure as early-stage biotech funding tightened
• Greystar 465K SF life science building (15 stories, just outside Cambridge) delivered early 2025 and remains vacant — an indicator of absorption headwinds for spec lab product
• Suburban corridors (Watertown, Waltham, Wilmington) are attracting tenants seeking budget-friendly alternatives to East Cambridge; cGMP manufacturing expanding to Route 128 and 495 corridors where land and ceiling height allow
• The Boston metro page covers the broader Boston market; life sciences is centered in Cambridge and the Route 128 corridor
• CBRE's Q1 2026 Cambridge office figures are not a lab-market source, but they add an adjacent occupancy caution for the Cambridge real-estate stack: 24.7% office availability, 21.7% office vacancy, and negative East Cambridge office absorption. Keep this separate from lab-specific vacancy and rent metrics, but use it as a warning against treating Cambridge demand as uniformly tight across product types.

San Diego / Torrey Pines

The third-largest U.S. life sciences market by lab inventory (27.3M SF). UCSD / Scripps / Salk Institute anchor demand. Torrey Pines Mesa and Sorrento Valley are the primary lab nodes; UTC (University Town Center) is the newest active development submarket (Alexandria Campus Point Megacampus, 466K SF for Novartis).

Key characteristics:

• Strong genomics and oncology tenant base (Illumina, Neurocrine Biosciences, Arctus Biotherapeutics)
• Lower rents than Boston/Cambridge but same FDA-moat structural dynamics
• Q4 2025 (Savills/CBRE): Overall vacancy increased 61.6% YoY to 28.6%, driven by 3M+ SF of new deliveries. Torrey Pines wet lab availability 29% (~1.2M SF including 500K+ SF sublease in 14 subleases). Five former Pfizer buildings expected to push Torrey Pines availability to a record-breaking ~45%. Class A lab rents declined for 14th consecutive quarter to $5.86/SF/mo NNN ($70/SF/yr).
• Q3 2025: 26.5% vacancy (C&W; +780 bps YoY from 18.7%). Savills broader definition: 29.2%.
• VC funding: $19.7B cumulative 2019–2024; $3.3B in 2024 alone (3rd globally)
• NIH FY 2024 funding: $1B+ to San Diego organizations
• Core submarkets (Torrey Pines, UTC, Sorrento Mesa, Sorrento Valley) led Q4 leasing activity but many options have been on the market for 1-2+ years — particularly wet lab conversions and spec construction
• US speculative construction collapsed to 2.4M SF nationally in 2025 (from 15.4M SF peak in 2022) — the pipeline shutoff is the recovery mechanism
• See San Diego for industrial and cross-border context

San Francisco Bay Area

The Bay Area life sciences market overlaps with its AI and technology office market in South San Francisco (SSF) — the original biotech corridor — and is expanding into Oakland and the East Bay.

Key characteristics:

• Genentech campus in SSF is the founding institution of the modern biotech industry
• SSF / Brisbane corridor is the primary established lab node
• Public city materials checked in April 2026 describe South San Francisco as the birthplace of biotechnology with approximately 12 million square feet of biotech space and nearly 250 active biotech companies
• The best current public market proxy is San Mateo County rather than South San Francisco alone: C&W Q2 2025 reported 29.8M SF inventory, 31.8% vacancy, $6.42 PSF monthly NNN asking rent, and 540,878 SF under construction
• SF AI office recovery (Anthropic, OpenAI) is driving office demand; lab demand is distinct and concentrated in SSF
• See South San Francisco Life Sciences Corridor for the corridor-level split; San Francisco remains the AI office recovery node

Tier 2 Clusters: Growth Markets

These markets have meaningful and growing life sciences demand but lack the depth and self-perpetuating density of the Tier 1 set. They are capturing NIH funding growth, university-affiliated startups, and some overflow from saturated Tier 1 markets.

Raleigh-Durham / Research Triangle

The Research Triangle (UNC, Duke, NC State, Research Triangle Park) is the strongest Tier 2 life sciences market in the U.S. by university anchor quality.

Key tenant base: GlaxoSmithKline (major campus in RTP), Biogen (cGMP manufacturing — $2.0B expansion announced 2025), IQVIA (scaling Durham global HQ), Eli Lilly, Pfizer, Novartis, Thermo Fisher Scientific, FUJIFILM Diosynth, bluebird bio. 675+ life sciences companies in the Research Triangle Region; 300+ inside RTP itself; 7 of the top 10 global CROs operate here (birthplace of the CRO industry via Quintiles/IQVIA, 1982). The Triangle also benefits from NIH-funded clinical research at the UNC Lineberger Comprehensive Cancer Center and Duke Cancer Center.

Major committed investments (2024-2026):

• Novo Nordisk — $4.1B investment in North Carolina (largest single pharma commitment in state history)
• Biogen — $2.0B manufacturing expansion in RTP
• FUJIFILM Diosynth — expanding CDMO capacity for biologics
• In 2024 alone, 25 life sciences companies announced NC projects — 4,500+ new jobs and $10.8B in committed investment statewide

Q1 2026 market conditions (Cushman & Wakefield local MarketBeat):

• Total inventory: 11,697,735 SF, with RTP/I-40 Corridor accounting for most of the base
• Overall vacancy: 27.6%, down 120 bps QoQ and the lowest level in six quarters under C&W's local series
• Sublease vacancy: 4.1%, down 10 bps QoQ
• Net absorption: +142,352 SF in Q1 / YTD, driven primarily by major tenant move-ins in RTP / I-40
• New leasing activity: 73,306 SF, with renewals excluded
• Under construction and completions: 0 SF
• Asking rent: $39.15/SF NNN
• The vacancy reset still reflects the same post-2022 biotech funding correction seen in Boston and San Diego, compressed into a smaller inventory base, but the local Q1 report supports stabilization rather than continued deterioration. Recovery will depend on NIH funding stabilization, cGMP / manufacturing demand, and the pace of tenant graduations from RTP incubator space.

The conversion opportunity remains active: existing industrial and flex-industrial buildings near RTP are feasible industrial-to-lab conversion candidates. The current sublease wave has created a buyer's market for lab space, which is likely to suppress new construction demand until vacancy stabilizes materially below current levels — the pipeline shutoff (0 SF under construction) is consistent with this dynamic.

See Charlotte and Raleigh-Durham for the metro context.

Houston / Texas Medical Center

The Texas Medical Center is the largest medical complex in the world by building square footage. TMC's Helix Park (37-acre campus) anchors Houston's life sciences ambitions:

• TMC3 Collaborative Building: 250,000 SF opened; 37-acre Helix Park campus ultimately planned for ~5M SF
• 425+ biotech startups currently based at TMC
• 10M patient encounters/year — a dataset that is increasingly relevant for AI-driven medical research and clinical trial design
• Phase I: research and collaboration; Phase II/III: expand cGMP manufacturing and clinical-stage company space

Houston's life sciences CRE thesis is tied to the TMC more than any other single asset in the knowledge base. The medical center functions as a demand anchor in a way that is different from the VC-and-startup dynamics of Boston and San Francisco — it is institution-driven, not venture-driven.

See Texas Medical Center District for the geographic detail.

Dallas / Pegasus Park

Dallas's life sciences presence is anchored at Pegasus Park — a 26-acre campus built on the former Zale Corporation headquarters site near the Medical District.

Key facts:

• BioLabs Pegasus Park: 37,000 SF incubator; opened 2022
• Bridge Labs at Pegasus Park: 135,000 SF scale-up graduation space for biotech startups
• Multiple North Texas university partners (UT Southwestern, UT Dallas, SMU, UNT)
• Dallas-Fort Worth lacks the established biopharma tenant depth of Boston, San Diego, or even RTP — but Pegasus Park is building the graduation infrastructure needed to retain companies that would otherwise move to coastal clusters

The 2026 Demand Shift: cGMP over Lab-Office

The 2021–2022 biotech funding boom created a wave of lab-office leasing. That wave has receded. The dominant 2026 demand theme is cGMP manufacturing — driven by the BioSecure Act (onshoring from China-linked CDMOs) and IRA biologics pricing protection (13 years for complex biologics).

This matters geographically because:

• cGMP manufacturing requires suburban or exurban sites with land for single-story buildings, heavy power and utilities, and wastewater capacity
• It is moving life sciences demand away from dense urban lab-office nodes (Kendall Square, South SF) toward suburban corridors in established clusters and Tier 2 markets
• Markets with available industrial-grade land and experienced biotech construction teams are positioned to capture cGMP overflow

Boston's suburban Route 128 and 495 corridors, Research Triangle Park's outer ring, and Houston's TMC Helix Park expansion phases are all positioned for this shift.

Cross-Cluster Comparison Table (Q4 2025)

National pattern: All three Tier 1 clusters are experiencing the same post-2022 correction — vacancy surges driven by biotech funding pullback and spec construction deliveries. The recovery mechanism is identical across all three: pipeline shutoff (U.S. spec lab construction collapsed from 15.4M SF peak in 2022 to 2.4M SF in 2025). Tier 2 markets are positioned to capture cGMP overflow and are accelerating through committed pharma manufacturing investment rather than VC-driven lab-office leasing.

June 2026 GlobeSt metadata adds a current directional marker to this pattern: public descriptions framed U.S. lab availability as beginning to contract after the correction and San Diego as showing positive first-quarter absorption alongside its best venture-capital pace since 2021. Treat that as a recovery watch item, not as proof that the high-availability phase is over. The captures preserve public metadata and descriptions but not full article bodies. See Source: GlobeSt Life Sciences Recovery After Lab Space Correction 2026 and Source: GlobeSt San Diego Life Sciences VC Pace 2026.

Source: Cushman & Wakefield U.S. Life Sciences MarketBeat Q1 2026 turns that directional recovery watch item into a source-family baseline. C&W's Q1 2026 table reported U.S. life-sciences vacancy at 23.6%, weighted asking rent at $65.48/SF, national net absorption essentially flat at -23,659 SF, and 5.35M SF under construction. The key geography signal is dispersion: Boston and New York City still screened very loose under C&W's definition, while Philadelphia and Los Angeles-Orange County screened much tighter. Use that as a prompt for source-labeled market diligence, not as a blended national rank.

Source: CBRE Q1 2026 U.S. Life Sciences Figures adds a CBRE top-13 lab/R&D denominator to the cross-cluster read. CBRE reported 23.2% vacancy, a 30 bps QoQ vacancy increase, -1.2M SF of negative absorption across nine of 13 major markets, $67.30/SF average NNN rent, 4.7M SF under construction, and $7.4B of Q1 venture-capital investment. The CBRE read confirms that capital formation improved before space demand fully healed, and it should stay source-labeled because it is not the same denominator as the C&W lab/cGMP table below.

Source: Transwestern U.S. Market Life Sciences Q1 2026 adds a qualified-inventory denominator across 11 visible markets plus a national total. Transwestern reported lower national direct vacancy than C&W and CBRE at 13.5%, but also reported -462,974 SF of Q1 net absorption and a clear east/west split: eastern markets were negative by 740,550 SF while western markets were positive by 355,170 SF. Use the table below as a Transwestern source-family screen, especially for markets where C&W / CBRE coverage is thinner or denominators differ.

Source: CBRE 2026 U.S. Life Sciences Trends adds a CBRE outlook overlay rather than another cross-cluster denominator. The useful geography implication is timing: CBRE says lab / R&D construction is projected to hit a 10-year low and major markets are getting relief from supply pressure, while capital re-engagement and renewed VC activity may support future lab demand. That helps explain why Tier 1 and Tier 2 clusters can be watchlist opportunities even while current vacancy remains elevated.

Source: Newmark 1Q26 U.S. Life Science Market Conditions & Trends adds a bounded national overlay: Newmark describes early stabilization in capital and biotech indicators, but says real-estate fundamentals have not materially improved and development has largely shut down. Its emphasis on top-tier assets, selective later-stage / AI-enabled funding, and manufacturing investment supports a cluster rule with two filters: deep ecosystems may reach recovery first, while manufacturing-led demand still requires site, utility, tenant-credit, and timing validation. The public landing page does not provide a market-by-market table, so do not use it to rank clusters.

Source: CBRE Boston Metro Life Science Figures Q1 2026 adds a current Boston-specific denominator to the same warning. Greater Boston still had 32.7% lab availability, 27.9% vacancy, and negative Q1 absorption despite improvement from Q4 2025. Use it to keep Boston in the Tier 1 bucket by cluster depth, but not to underwrite generic lab-office beta as if the oversupply cycle has cleared.

Source: CBRE New York City Life Sciences Figures Q1 2026 adds a smaller-market Northeast comparator. NYC showed only 27,000 SF of Q1 leasing velocity, 27.5% lab-exclusive availability, 11.6% occupancy-ready built-lab availability, $96.43/SF lab-exclusive asking rent, and $263.65M of quarterly life-sciences venture funding. The source supports NYC as an expensive institutional-medical / venture ecosystem watchlist node, not as a broad lab allocation market.

Source: CBRE Denver/Boulder Life Sciences Figures Q1 2026 adds a Front Range emerging-cluster comparator. Denver/Boulder had 85,000 SF of Q1 leasing, 12.7% direct vacancy, 18.4% Boulder direct vacancy, $205M of Q1 VC funding, and a 221,000 SF pipeline. The useful signal is not scale; it is that smaller clusters can screen better on vacancy and pipeline discipline than oversupplied Tier 1 markets while still requiring tenant-depth and inventory diligence.

Source: CBRE Puget Sound Life Science Figures H2 2025 adds a dedicated CBRE Puget Sound source-family row behind Seattle's second-tier-cluster status. The H2 2025 page reported 21.2% total vacancy, -97,208 SF of 2025 net absorption, 39.0% investor-owned availability, and meaningful but narrow node evidence: Bothell leasing by SystImmune / AGC Biologics, 701 Dexter's South Lake Union delivery, and Alexandria's planned Bellevue / Wilburton campus. Use Seattle as a credible specialist cluster with institutional anchors and pipeline discipline, not as a scaled Tier 1 allocation market.

C&W Q1 2026 Cross-Cluster Check

Transwestern Q1 2026 Cross-Cluster Check

Cross-Market Underwriting Principles

Life sciences cluster geography creates underwriting rules that are distinctly different from commodity industrial or office:

1. Cluster gravity is strong. Tenants in Kendall Square or Torrey Pines do not relocate to cheaper markets because they cannot replicate talent proximity and FDA-validation histories at a new site. This makes established clusters structurally tight in ways that do not respond to normal rent signals.

2. Emerging markets need graduation infrastructure. A Tier 2 market only works if there is a pathway from incubator → scale-up → standalone campus. Pegasus Park and TMC Helix Park are building this explicitly. Markets without a graduation infrastructure stack lose companies to Tier 1 clusters at Series B/C.

3. cGMP re-tenanting risk is extreme. See Life Sciences and Lab Underwriting for the TI reload risk ($150–$500/SF re-commissioning cost). This makes tenant credit and lease term the primary underwriting variable in cGMP assets, not market rent.

4. NIH funding geography tracks cluster investment. Tracking NIH SBIR/STTR awards by metro gives a leading indicator of where biotech startup demand will concentrate in 2–5 years.

Gaps

• No standalone South San Francisco geography page despite repeated biotech-corridor references
• NIH funding distribution not tracked in DB
• cGMP manufacturing capacity by market not yet quantified
• VC biotech funding by metro not tracked
• Boston life sciences page exists (see Boston) but does not break out Kendall Square from broader metro
• San Diego Q4 2025 Savills report (28.6% vacancy) not imported to DB
• Boston Q4 2025 LPC/CBRE lab data (28% metro vacancy, 12.7% Cambridge) not imported to DB
• Alexandria $30M RTP site sale (Bisnow 2026) not yet ingested

Related Pages

• National Life Sciences Capital Allocation 2026 — capital-deployment read-through across Tier 1, Tier 2, and emerging Texas nodes
• Life Sciences and Lab Underwriting — underwriting framework: cGMP benchmarks, TI risk, FDA moat, BioSecure Act
• Boston — Tier 1 cluster; Kendall Square / Route 128
• San Francisco — downtown San Francisco and SoMa AI office recovery
• South San Francisco Life Sciences Corridor — Bay Area biotech corridor split from the SF office node
• Raleigh-Durham — Tier 2; Research Triangle; GSK, Biogen, Novo Nordisk, IQVIA
• Charlotte and Raleigh-Durham — Carolinas corridor context
• Texas Medical Center District — Houston Tier 2 anchor
• Dallas-Fort Worth — Dallas Pegasus Park incubator / graduation infrastructure
• Industrial Hub — cGMP manufacturing sits in the industrial asset class, not office
• Sun Belt Geography Hub
• Carolinas CRE Allocation 2026 — Carolinas comparison; life sciences is the key differentiator

Sources

• Life Sciences and Lab Underwriting — BioSecure Act, cGMP benchmarks, IRA biologics pricing
• Source: Life Sciences: The Next Frontier for Commercial Real Estate in Texas? — JLL 2025 Texas life sciences report; Pegasus Park details; TMC Helix Park; Texas market sizing
• LPC Lab Report Boston Q4 2025 — Cambridge 12.7% vacancy, metro 28% all-time high
• Savills San Diego Q4 2025 Life Sciences Market Report — 28.6% vacancy, Torrey Pines 29%
• Source: Cushman & Wakefield U.S. Life Sciences MarketBeat Q1 2026 — national C&W life-sciences table, market rows, capital-market indicators, and pipeline mix
• Source: CBRE Q1 2026 U.S. Life Sciences Figures — CBRE top-13 lab/R&D vacancy, rent, absorption, construction, and VC-funding summary
• Source: Transwestern U.S. Market Life Sciences Q1 2026 — Transwestern qualified-inventory table for national and 11 visible market rows, plus VC, IPO, and NIH-funding context
• CBRE San Diego Q4 2024 Life Sciences Market Overview — prior-period baseline
• Source: GlobeSt Life Sciences Recovery After Lab Space Correction 2026 — June 2026 public metadata / description for early lab-availability recovery signal
• Source: GlobeSt San Diego Life Sciences VC Pace 2026 — June 2026 public metadata / description for San Diego VC and Q1 absorption watch item
• Source: Newmark 1Q26 U.S. Life Science Market Conditions & Trends — bounded national stabilization and manufacturing-investment overlay; no market table
• NC Biotechnology Center — 840 life science companies in NC; 675+ in Triangle Region
• Labiotech: Research Triangle Park biotech hotspot — CRO birthplace, 300+ RTP companies